Craig Coleman
Professor/Pharmacy Practice

Are you Craig Coleman?

How to update your information.
Scholarly Contributions

620 Scholarly Contributions

419
Journal Articles
137
Poster/Presentations
41
Other Scholarly Works
12
Digital and Electronic Media, Social Media, Blog, Podcast, Magazine/Trade Publications
6
Conference Proceedings
5
Book Chapters
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis.
2020
B Miao, Thomas Bunz, Craig Coleman, N Sood
Research Type: Journal Article

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data.
2020
Craig Coleman, K T Moore, O S Costa, V Ashton, J Beyer-Westendorf, D Milentijevic, Thomas Bunz
Research Type: Journal Article

Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation.
2020
B Miao, M J Alberts, William L Baker Jr., Adrian V Hernandez Diaz, Y M Roman, Craig Coleman
Research Type: Journal Article

Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
2020
B Bookhart, Craig Coleman, E R Weeda, A Kharat, William L Baker Jr.
Research Type: Journal Article

Real-World Hemostatic Effectiveness of Andexanet Alfa for Management of Intracerebral Hemorrhage
2020
Craig Coleman, William L Baker Jr., Olivia S Costa
Research Type: Poster/Presentation

“OUTCOMES ASSOCIATED WITH BLEEDING-RELATED HOSPITALIZATIONS IN PATIENTS AT HIGH THROMBOTIC RISK FINDINGS FROM THE NATIONWIDE READMISSION DATABASE”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

Does Rivaroxaban Reduce the Development of Renal failure Compared to Vitamin K Antagonist Use in Nonvalvular Atrial Fibrillation Patients? A Systematic Review and Meta-Analysis
2020
Craig Coleman
Research Type: Poster/Presentation

Methodological and Reporting Quality in Case Series of Four-Factor Prothrombin Complex Concentrate in the Management of Oral Factor Xa Inhibitor-Associated Bleeding,
2020
Craig Coleman
Research Type: Poster/Presentation

Does one size fits all for NVAF patients with comorbidities?
2020
Craig Coleman
Research Type: Poster/Presentation

“Four-Year Incidence of Major Adverse Cardiovascular Events in Patients With Established Cerebrovascular Disease”. Event: ISC 2020, Los Angeles.
2020
Craig Coleman
Research Type: Poster/Presentation

Rivaroxaban Versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients
2020
Craig Coleman
Research Type: Poster/Presentation

Do Difference in Baseline Clinical Severity of Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage Predict Andexanet Versus Four-Factor Prothrombin Complex Concentrate Administration?
2020
William L Baker Jr., Olivia S Costa, Craig Coleman
Research Type: Poster/Presentation

“RIVAROXABAN VERSUS WARFARIN IN AFRICAN AMERICAN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

“REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

Effectiveness and Safety of Rivaroxaban Compared to Low Molecular-Weight Heparin in Patients with Cancer-Associated Venous Thromboembolism: A Real-World Analysis.
2020
Craig Coleman
Research Type: Poster/Presentation

Do Differences in Baseline Clinical Severity of Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage Predict Andexanet Alfa Versus Four-Factor Prothrombin Complex Concentrate Administration?
2020
Craig Coleman
Research Type: Poster/Presentation

“FOUR-YEAR INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS WITH OR AT HIGH RISK FOR ATHEROSCLEROSIS”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
2021
N Sood, O S Costa, Craig Coleman, C W Brescia, B Vardar, K Abdelgawwad
Research Type: Journal Article

Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
2021
Craig Coleman, B Vardar, B O'Donnell, N Sood, C W Brescia, O S Costa, K Abdelgawwad
Research Type: Journal Article

Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
2021
S Danese, Craig Coleman, J Ulloa, P P Dobesh, B Lovelace
Research Type: Journal Article